Endoscopic cardiac tumor resection.

Department of Cardiovascular and Thoracic Surgery, OLV Clinic, Aalst, Belgium.
The Annals of thoracic surgery (Impact Factor: 3.45). 07/2007; 83(6):2142-6. DOI: 10.1016/j.athoracsur.2007.01.064
Source: PubMed

ABSTRACT The purpose of this study is to report our 9 years' experience with endoscopic cardiac tumor resection using the port access approach.
From March 1997 to December 2005, 27 patients (mean age, 56.2 +/- 16.9 years; 70% female) underwent endoscopic cardiac tumor resection using endocardiopulmonary bypass and endoaortic-balloon clamp technique. Nineteen (70%) patients presented in New York Heart Association class I, 4 patients presented with embolic stroke, and 4 patients presented with atrial arrhythmias. All patients underwent echocardiography on admission, intraoperatively, at discharge, and at follow-up evaluation. Eight patients additionally required mitral valve replacement (n = 1), tricuspid valve replacement (n = 1), mitral valve repair (n = 2), mini-maze (n = 1), and closure of patent foramen ovale (n = 3). Mean follow-up was 3.4 +/- 2.7 years.
Mean endoaortic-balloon clamp and endocardiopulmonary bypass times were 68.8 +/- 30.8 minutes and 112.2 +/- 41.5 minutes, respectively. There were no conversions to sternotomy. Tumors resected were classified as left atrial myxoma (n = 20), right atrial myxoma (n = 3), lipoma (n = 1), intravenous leiomyoma involving the inferior vena cava and the tricuspid valve (n = 1), plexiform tumor of the sinoatrial node (n = 1), and papillary fibroelastoma of aortic valve noncoronary cusp (n = 1). There were no hospital deaths. Mean intensive care unit and hospital stays were 1.4 +/- 1.1 days and 7.3 +/- 3.4 days, respectively. Postoperative complications were evolving stroke (n = 1), re-exploration for bleeding (n = 1), and myocardial ischemia requiring stenting (n = 1). Follow-up failed to demonstrate residual or recurrent tumor. One patient had a small residual atrial septal defect. Ninety-two percent of patients appreciated the cosmetic result and fast recovery.
Endoscopic cardiac tumor resection is feasible and a valid oncologic approach with an attractive cosmetic advantage over median sternotomy.

  • Methods in Enzymology - METH ENZYMOLOGY. 01/2004; 378:67-87.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Resection of cardiac tumors in the right ventricle sometimes requires valve plasty or replacement. We retrospectively studied surgical treatment for right ventricular tumors. The study cohort consists of 210 consecutive patients who underwent surgical treatment for a cardiac tumor in our hospital between January 1990 and December 2008. Clinical findings were reviewed retrospectively, and a follow-up study was performed. Of 210 cardiac tumors, 17 were located in the right ventricle. Of these17 right ventricular (RV) tumors, 13 were endocardial or intracavitary tumors, and 4 were epicardial tumors. Of the 17 patients, 5 underwent concomitant tricuspid valve surgery. Three of the five patients had endocardial tumors and underwent Kay annuloplasty; the other two had epicardial tumors, one of whom underwent reconstruction of the tricuspid annulus by suturing of an autologous pericardial strip, and one had tricuspid valve replacement with a 31-mm Hancock valve. Of the five patients with concomitant tricuspid valve surgery, none had an increase to grade 3 tricuspid regurgitation during follow-up. Tricuspid valve annuloplasty for resection of RV tumors may be necessary, even for palliative operations, to improve the hemodynamics.
    General Thoracic and Cardiovascular Surgery 07/2010; 58(7):317-22.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac tumors are assumed to be a rare entity. Metastases to the heart are more frequent than primary lesions. Sarcomas make up the majority of cardiac malignant neoplasms. Among them angiosarcoma is the most common and associated with the worst prognosis. Malignant fibrous histiocytoma comprises the minority of cardiac sarcomas and has uncertain etiology as well as pathogenesis. Transthoracic echocardiography remains the widely available screening examination for the initial diagnosis of a cardiac tumor. The clinical presentation is non-specific and the diagnosis is established usually at an advanced stage of the disease. Sarcomas spread preferentially through blood due to their immature vessels without endothelial lining. Surgery remains the method of choice for treatment. Radicalness of the excision is still the most valuable prognostic factor. Adjuvant therapy is unlikely to be effective. The management of cardiac sarcomas must be individualized due to their rarity and significant differences in the course of disease.
    Archives of Medical Science 02/2014; 10(1):135-48. · 1.89 Impact Factor

Full-text (2 Sources)

Available from
May 30, 2014